Scientist I, Bioconjugate Lead - Protein Sciences

Ampersand Biomedicines•Watertown, MA

5d•$100,000 - $143,000

About The Position

Ampersand is currently seeking a highly motivated scientist with a background in antibody-oligonucleotide/drug conjugate (AOC/ADC) and protein sciences to contribute to the discovery and development of AND-Body™ Therapeutics. This position will emphasize creating and analyzing new antibody modalities to develop biologic therapies targeted at specific tissues.

Requirements

Strong technical background in AOCs; direct experience with siRNA design, antibody engineering, bioconjugation chemistry, or oligonucleotide therapeutics is highly preferred.
PhD in Biochemistry, Chemical Biology, or a related scientific discipline with 2+ years of experience; exceptional candidates with significant experience and without a doctorate will be considered.
Hands-on experience in chromatography (ÄKTA, SEC, HIC, and IEX) and protein analytics (mass spectrometry, DLS).
Direct experience with aseptic mammalian cell culture and plasmid transfection.
Experience managing CROs.
Excellent written and verbal communication skills, with the ability to clearly interpret data and present results to project teams.

Nice To Haves

Demonstrated hands-on expertise with site-specific, bioorthogonal conjugation technologies (e.g., enzymatic conjugation, engineered cysteines).
Knowledge of linker chemistry and stability optimization strategies.
Experience in antibody purification and/or protein engineering.
Experience working in a biotech or translational research environment.
Strong statistical and data analysis skills.
Previous industry experience is advantageous but not required.

Responsibilities

Collaborate with cross-functional teams to develop AOC/ADC biomolecules that enable targeted delivery to tissues of high interest.
Co-lead AOC/ADC projects to advance therapeutic candidates, working closely with Ampersand stakeholders, advisors, and CRO collaborators.
Supervise the design and execution of studies, as well as in the interpretation of data for both in vitro and in vivo research.
Develop a state-of-the-art platform to facilitate biophysical and biochemical analyses of novel antibody modalities.